Eintrag weiter verarbeiten
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features
Gespeichert in:
| Zeitschriftentitel: | Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , , , , |
| In: | Cancer Research, 80, 2020, 4, S. 843-856 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Marqués, Miriam Tranchant, Robin Risa-Ebrí, Blanca Suárez-Solís, María L. Fernández, Luis C. Carrillo-de-Santa-Pau, Enrique del Pozo, Natalia Martínez de Villarreal, Jaime Meiller, Clément Allory, Yves Blum, Yuna Pirker, Christine Hegedus, Balazs Barry, Simon T. Carnero, Amancio Berger, Walter Jean, Didier Real, Francisco X. Marqués, Miriam Tranchant, Robin Risa-Ebrí, Blanca Suárez-Solís, María L. Fernández, Luis C. Carrillo-de-Santa-Pau, Enrique del Pozo, Natalia Martínez de Villarreal, Jaime Meiller, Clément Allory, Yves Blum, Yuna Pirker, Christine Hegedus, Balazs Barry, Simon T. Carnero, Amancio Berger, Walter Jean, Didier Real, Francisco X. |
|---|---|
| author |
Marqués, Miriam Tranchant, Robin Risa-Ebrí, Blanca Suárez-Solís, María L. Fernández, Luis C. Carrillo-de-Santa-Pau, Enrique del Pozo, Natalia Martínez de Villarreal, Jaime Meiller, Clément Allory, Yves Blum, Yuna Pirker, Christine Hegedus, Balazs Barry, Simon T. Carnero, Amancio Berger, Walter Jean, Didier Real, Francisco X. |
| spellingShingle |
Marqués, Miriam Tranchant, Robin Risa-Ebrí, Blanca Suárez-Solís, María L. Fernández, Luis C. Carrillo-de-Santa-Pau, Enrique del Pozo, Natalia Martínez de Villarreal, Jaime Meiller, Clément Allory, Yves Blum, Yuna Pirker, Christine Hegedus, Balazs Barry, Simon T. Carnero, Amancio Berger, Walter Jean, Didier Real, Francisco X. Cancer Research Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features Cancer Research Oncology |
| author_sort |
marqués, miriam |
| spelling |
Marqués, Miriam Tranchant, Robin Risa-Ebrí, Blanca Suárez-Solís, María L. Fernández, Luis C. Carrillo-de-Santa-Pau, Enrique del Pozo, Natalia Martínez de Villarreal, Jaime Meiller, Clément Allory, Yves Blum, Yuna Pirker, Christine Hegedus, Balazs Barry, Simon T. Carnero, Amancio Berger, Walter Jean, Didier Real, Francisco X. 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/0008-5472.can-19-1633 <jats:title>Abstract</jats:title> <jats:sec> <jats:title /> <jats:p>Among malignant mesotheliomas (MM), the sarcomatoid subtype is associated with higher chemoresistance and worst survival. Due to its low incidence, there has been little progress in the knowledge of the molecular mechanisms associated with sarcomatoid MM, which might help to define novel therapeutic targets. In this work, we show that loss of PTEN expression is frequent in human sarcomatoid MM and PTEN expression levels are lower in sarcomatoid MM than in the biphasic and epithelioid subtypes. Combined Pten and Trp53 deletion in mouse mesothelium led to nonepithelioid MM development. In Pten;Trp53-null mice developing MM, the Gαi2-coupled receptor subunit activated MEK/ERK and PI3K, resulting in aggressive, immune-suppressed tumors. Combined inhibition of MEK and p110β/PI3K reduced mouse tumor cell growth in vitro. Therapeutic inhibition of MEK and p110β/PI3K using selumetinib (AZD6244, ARRY-142886) and AZD8186, two drugs that are currently in clinical trials, increased the survival of Pten;Trp53-null mice without major toxicity. This drug combination effectively reduced the proliferation of primary cultures of human pleural (Pl) MM, implicating nonepithelioid histology and high vimentin, AKT1/2, and Gαi2 expression levels as predictive markers of response to combined MEK and p110β/PI3K inhibition. Our findings provide a rationale for the use of selumetinib and AZD8186 in patients with MM with sarcomatoid features. This constitutes a novel targeted therapy for a poor prognosis and frequently chemoresistant group of patients with MM, for whom therapeutic options are currently lacking.</jats:p> </jats:sec> <jats:sec> <jats:title>Significance:</jats:title> <jats:p>Mesothelioma is highly aggressive; its sarcomatoid variants have worse prognosis. Building on a genetic mouse model, a novel combination therapy is uncovered that is relevant to human tumors.</jats:p> </jats:sec> Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features Cancer Research |
| doi_str_mv |
10.1158/0008-5472.can-19-1633 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTE5LTE2MzM |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTE5LTE2MzM |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Association for Cancer Research (AACR), 2020 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2020 |
| issn |
0008-5472 1538-7445 |
| issn_str_mv |
0008-5472 1538-7445 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
marques2020combinedmekandpi3kp110binhibitionasanoveltargetedtherapyformalignantmesotheliomadisplayingsarcomatoidfeatures |
| publishDateSort |
2020 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancer Research |
| source_id |
49 |
| title |
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_unstemmed |
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_full |
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_fullStr |
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_full_unstemmed |
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_short |
Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_sort |
combined mek and pi3k/p110β inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/0008-5472.can-19-1633 |
| publishDate |
2020 |
| physical |
843-856 |
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title />
<jats:p>Among malignant mesotheliomas (MM), the sarcomatoid subtype is associated with higher chemoresistance and worst survival. Due to its low incidence, there has been little progress in the knowledge of the molecular mechanisms associated with sarcomatoid MM, which might help to define novel therapeutic targets. In this work, we show that loss of PTEN expression is frequent in human sarcomatoid MM and PTEN expression levels are lower in sarcomatoid MM than in the biphasic and epithelioid subtypes. Combined Pten and Trp53 deletion in mouse mesothelium led to nonepithelioid MM development. In Pten;Trp53-null mice developing MM, the Gαi2-coupled receptor subunit activated MEK/ERK and PI3K, resulting in aggressive, immune-suppressed tumors. Combined inhibition of MEK and p110β/PI3K reduced mouse tumor cell growth in vitro. Therapeutic inhibition of MEK and p110β/PI3K using selumetinib (AZD6244, ARRY-142886) and AZD8186, two drugs that are currently in clinical trials, increased the survival of Pten;Trp53-null mice without major toxicity. This drug combination effectively reduced the proliferation of primary cultures of human pleural (Pl) MM, implicating nonepithelioid histology and high vimentin, AKT1/2, and Gαi2 expression levels as predictive markers of response to combined MEK and p110β/PI3K inhibition. Our findings provide a rationale for the use of selumetinib and AZD8186 in patients with MM with sarcomatoid features. This constitutes a novel targeted therapy for a poor prognosis and frequently chemoresistant group of patients with MM, for whom therapeutic options are currently lacking.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Significance:</jats:title>
<jats:p>Mesothelioma is highly aggressive; its sarcomatoid variants have worse prognosis. Building on a genetic mouse model, a novel combination therapy is uncovered that is relevant to human tumors.</jats:p>
</jats:sec> |
| container_issue |
4 |
| container_start_page |
843 |
| container_title |
Cancer Research |
| container_volume |
80 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348158378901507 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:06:41.414Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Combined+MEK+and+PI3K%2Fp110%CE%B2+Inhibition+as+a+Novel+Targeted+Therapy+for+Malignant+Mesothelioma+Displaying+Sarcomatoid+Features&rft.date=2020-02-15&genre=article&issn=1538-7445&volume=80&issue=4&spage=843&epage=856&pages=843-856&jtitle=Cancer+Research&atitle=Combined+MEK+and+PI3K%2Fp110%CE%B2+Inhibition+as+a+Novel+Targeted+Therapy+for+Malignant+Mesothelioma+Displaying+Sarcomatoid+Features&aulast=Real&aufirst=Francisco+X.&rft_id=info%3Adoi%2F10.1158%2F0008-5472.can-19-1633&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348158378901507 |
| author | Marqués, Miriam, Tranchant, Robin, Risa-Ebrí, Blanca, Suárez-Solís, María L., Fernández, Luis C., Carrillo-de-Santa-Pau, Enrique, del Pozo, Natalia, Martínez de Villarreal, Jaime, Meiller, Clément, Allory, Yves, Blum, Yuna, Pirker, Christine, Hegedus, Balazs, Barry, Simon T., Carnero, Amancio, Berger, Walter, Jean, Didier, Real, Francisco X. |
| author_facet | Marqués, Miriam, Tranchant, Robin, Risa-Ebrí, Blanca, Suárez-Solís, María L., Fernández, Luis C., Carrillo-de-Santa-Pau, Enrique, del Pozo, Natalia, Martínez de Villarreal, Jaime, Meiller, Clément, Allory, Yves, Blum, Yuna, Pirker, Christine, Hegedus, Balazs, Barry, Simon T., Carnero, Amancio, Berger, Walter, Jean, Didier, Real, Francisco X., Marqués, Miriam, Tranchant, Robin, Risa-Ebrí, Blanca, Suárez-Solís, María L., Fernández, Luis C., Carrillo-de-Santa-Pau, Enrique, del Pozo, Natalia, Martínez de Villarreal, Jaime, Meiller, Clément, Allory, Yves, Blum, Yuna, Pirker, Christine, Hegedus, Balazs, Barry, Simon T., Carnero, Amancio, Berger, Walter, Jean, Didier, Real, Francisco X. |
| author_sort | marqués, miriam |
| container_issue | 4 |
| container_start_page | 843 |
| container_title | Cancer Research |
| container_volume | 80 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title /> <jats:p>Among malignant mesotheliomas (MM), the sarcomatoid subtype is associated with higher chemoresistance and worst survival. Due to its low incidence, there has been little progress in the knowledge of the molecular mechanisms associated with sarcomatoid MM, which might help to define novel therapeutic targets. In this work, we show that loss of PTEN expression is frequent in human sarcomatoid MM and PTEN expression levels are lower in sarcomatoid MM than in the biphasic and epithelioid subtypes. Combined Pten and Trp53 deletion in mouse mesothelium led to nonepithelioid MM development. In Pten;Trp53-null mice developing MM, the Gαi2-coupled receptor subunit activated MEK/ERK and PI3K, resulting in aggressive, immune-suppressed tumors. Combined inhibition of MEK and p110β/PI3K reduced mouse tumor cell growth in vitro. Therapeutic inhibition of MEK and p110β/PI3K using selumetinib (AZD6244, ARRY-142886) and AZD8186, two drugs that are currently in clinical trials, increased the survival of Pten;Trp53-null mice without major toxicity. This drug combination effectively reduced the proliferation of primary cultures of human pleural (Pl) MM, implicating nonepithelioid histology and high vimentin, AKT1/2, and Gαi2 expression levels as predictive markers of response to combined MEK and p110β/PI3K inhibition. Our findings provide a rationale for the use of selumetinib and AZD8186 in patients with MM with sarcomatoid features. This constitutes a novel targeted therapy for a poor prognosis and frequently chemoresistant group of patients with MM, for whom therapeutic options are currently lacking.</jats:p> </jats:sec> <jats:sec> <jats:title>Significance:</jats:title> <jats:p>Mesothelioma is highly aggressive; its sarcomatoid variants have worse prognosis. Building on a genetic mouse model, a novel combination therapy is uncovered that is relevant to human tumors.</jats:p> </jats:sec> |
| doi_str_mv | 10.1158/0008-5472.can-19-1633 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTE5LTE2MzM |
| imprint | American Association for Cancer Research (AACR), 2020 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2020 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0008-5472, 1538-7445 |
| issn_str_mv | 0008-5472, 1538-7445 |
| language | English |
| last_indexed | 2024-03-01T18:06:41.414Z |
| match_str | marques2020combinedmekandpi3kp110binhibitionasanoveltargetedtherapyformalignantmesotheliomadisplayingsarcomatoidfeatures |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 843-856 |
| publishDate | 2020 |
| publishDateSort | 2020 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Cancer Research |
| source_id | 49 |
| spelling | Marqués, Miriam Tranchant, Robin Risa-Ebrí, Blanca Suárez-Solís, María L. Fernández, Luis C. Carrillo-de-Santa-Pau, Enrique del Pozo, Natalia Martínez de Villarreal, Jaime Meiller, Clément Allory, Yves Blum, Yuna Pirker, Christine Hegedus, Balazs Barry, Simon T. Carnero, Amancio Berger, Walter Jean, Didier Real, Francisco X. 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/0008-5472.can-19-1633 <jats:title>Abstract</jats:title> <jats:sec> <jats:title /> <jats:p>Among malignant mesotheliomas (MM), the sarcomatoid subtype is associated with higher chemoresistance and worst survival. Due to its low incidence, there has been little progress in the knowledge of the molecular mechanisms associated with sarcomatoid MM, which might help to define novel therapeutic targets. In this work, we show that loss of PTEN expression is frequent in human sarcomatoid MM and PTEN expression levels are lower in sarcomatoid MM than in the biphasic and epithelioid subtypes. Combined Pten and Trp53 deletion in mouse mesothelium led to nonepithelioid MM development. In Pten;Trp53-null mice developing MM, the Gαi2-coupled receptor subunit activated MEK/ERK and PI3K, resulting in aggressive, immune-suppressed tumors. Combined inhibition of MEK and p110β/PI3K reduced mouse tumor cell growth in vitro. Therapeutic inhibition of MEK and p110β/PI3K using selumetinib (AZD6244, ARRY-142886) and AZD8186, two drugs that are currently in clinical trials, increased the survival of Pten;Trp53-null mice without major toxicity. This drug combination effectively reduced the proliferation of primary cultures of human pleural (Pl) MM, implicating nonepithelioid histology and high vimentin, AKT1/2, and Gαi2 expression levels as predictive markers of response to combined MEK and p110β/PI3K inhibition. Our findings provide a rationale for the use of selumetinib and AZD8186 in patients with MM with sarcomatoid features. This constitutes a novel targeted therapy for a poor prognosis and frequently chemoresistant group of patients with MM, for whom therapeutic options are currently lacking.</jats:p> </jats:sec> <jats:sec> <jats:title>Significance:</jats:title> <jats:p>Mesothelioma is highly aggressive; its sarcomatoid variants have worse prognosis. Building on a genetic mouse model, a novel combination therapy is uncovered that is relevant to human tumors.</jats:p> </jats:sec> Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features Cancer Research |
| spellingShingle | Marqués, Miriam, Tranchant, Robin, Risa-Ebrí, Blanca, Suárez-Solís, María L., Fernández, Luis C., Carrillo-de-Santa-Pau, Enrique, del Pozo, Natalia, Martínez de Villarreal, Jaime, Meiller, Clément, Allory, Yves, Blum, Yuna, Pirker, Christine, Hegedus, Balazs, Barry, Simon T., Carnero, Amancio, Berger, Walter, Jean, Didier, Real, Francisco X., Cancer Research, Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features, Cancer Research, Oncology |
| title | Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_full | Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_fullStr | Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_full_unstemmed | Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_short | Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| title_sort | combined mek and pi3k/p110β inhibition as a novel targeted therapy for malignant mesothelioma displaying sarcomatoid features |
| title_unstemmed | Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/0008-5472.can-19-1633 |